Clinical Trial Update: Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update presents long-term safety data for tobramycin inhalation powder in people with cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TOBI Podhaler (tobramycin inhalation powder)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2015-02-10